KDR and neoplasm: To examine whether growth of tumor-derived human blood vessels in our cranial window model also depends on VEGF signaling pathways, the anti-human VEGFR2 antibody ramucirumab was given three times a week from day 14 to day 21 after tumor transplantation (Fig. 5a).